Treating the patient and not just the cancer: therapeutic burden in prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
05
09
2020
accepted:
20
01
2021
revised:
12
01
2021
pubmed:
20
2
2021
medline:
2
2
2022
entrez:
19
2
2021
Statut:
ppublish
Résumé
Prostate cancer (PC) is a leading cause of death in older men. Androgen deprivation therapy (ADT) is considered the standard-of-care for men with locally advanced disease. However, continuous androgen ablation is associated with acute and long-term adverse effects and most patients will eventually develop castration-resistant PC (CRPC). The recent approval of three, second-generation androgen receptor inhibitors (ARIs), apalutamide, enzalutamide, and darolutamide, has transformed the treatment landscape of PC. Treatment with these second-generation ARIs have produced positive trends in metastasis-free survival, progression-free survival, and overall survival. For patients with non-metastatic CRPC, who are mainly asymptomatic from their disease, maintaining quality of life is a major objective when prescribing therapy. Polypharmacy for age-related comorbidities also is common in this population and may increase the potential for drug-drug interactions (DDIs). This review summarizes the multiple factors that may contribute to the therapeutic burden of patients with CRPC, including the interplay between age, comorbidities, concomitant medications, the use of ARIs, and financial distress. As the treatment landscape in PC continues to rapidly evolve, consideration must be given to the balance between therapeutic benefits and potential treatment-emergent adverse events that may be further complicated by DDIs with concomitant medications. Patient-centered communication is a crucial aspect of alleviating this burden, and healthcare professionals (HCPs) may benefit from training in effective patient communication. HCPs should closely and frequently monitor patient treatment responses, in order to better understand symptom onset and exacerbation. Patients also should be encouraged to participate in exercise programs, and health information and support groups, which may assist them in preventing or mitigating certain determinants of the therapeutic burden associated with PC and its management.
Sections du résumé
BACKGROUND
Prostate cancer (PC) is a leading cause of death in older men. Androgen deprivation therapy (ADT) is considered the standard-of-care for men with locally advanced disease. However, continuous androgen ablation is associated with acute and long-term adverse effects and most patients will eventually develop castration-resistant PC (CRPC). The recent approval of three, second-generation androgen receptor inhibitors (ARIs), apalutamide, enzalutamide, and darolutamide, has transformed the treatment landscape of PC. Treatment with these second-generation ARIs have produced positive trends in metastasis-free survival, progression-free survival, and overall survival. For patients with non-metastatic CRPC, who are mainly asymptomatic from their disease, maintaining quality of life is a major objective when prescribing therapy. Polypharmacy for age-related comorbidities also is common in this population and may increase the potential for drug-drug interactions (DDIs).
METHOD
This review summarizes the multiple factors that may contribute to the therapeutic burden of patients with CRPC, including the interplay between age, comorbidities, concomitant medications, the use of ARIs, and financial distress.
CONCLUSIONS
As the treatment landscape in PC continues to rapidly evolve, consideration must be given to the balance between therapeutic benefits and potential treatment-emergent adverse events that may be further complicated by DDIs with concomitant medications. Patient-centered communication is a crucial aspect of alleviating this burden, and healthcare professionals (HCPs) may benefit from training in effective patient communication. HCPs should closely and frequently monitor patient treatment responses, in order to better understand symptom onset and exacerbation. Patients also should be encouraged to participate in exercise programs, and health information and support groups, which may assist them in preventing or mitigating certain determinants of the therapeutic burden associated with PC and its management.
Identifiants
pubmed: 33603236
doi: 10.1038/s41391-021-00328-1
pii: 10.1038/s41391-021-00328-1
pmc: PMC8384628
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-661Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
United Nations. World population ageing 2019: highlights. https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf . Accessed April 17, 2020.
Orimo H. [Reviewing the definition of elderly]. Nihon Ronen Igakkai Zasshi 2006;43:27–34.
pubmed: 16521795
doi: 10.3143/geriatrics.43.27
Singh S, Bajorek B. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada) 2014;12:489–89.
doi: 10.4321/S1886-36552014000400007
Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol Ser A, Biol Sci Med Sci 2013;68:667–74.
doi: 10.1093/gerona/gls233
Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol 2014;11:317–23.
pubmed: 24818853
pmcid: 4191828
doi: 10.1038/nrurol.2014.91
Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int 2004;94:303–6.
pubmed: 15291856
doi: 10.1111/j.1464-410X.2004.04883.x
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 2017;29:377–85.
doi: 10.1093/annonc/mdx742
Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl J Med 2011;365:107–18.
pubmed: 21751904
doi: 10.1056/NEJMoa1012348
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10:63–89.
pubmed: 31068988
pmcid: 6497009
doi: 10.14740/wjon1191
American Cancer Society. Cancer facts & figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf . Accessed April 20, 2020.
Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. https://uroweb.org/guideline/prostate-cancer/ . Accessed May 7, 2020.
Luo J, Beer TM, Graff JN. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 2016;30:336–44.
pubmed: 27085332
Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer 2016;23:T179–T97.
pubmed: 27799360
doi: 10.1530/ERC-16-0422
Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas 2012;3:39–49.
pubmed: 23185121
pmcid: 3506008
doi: 10.2147/PROM.S34681
Gallacher K, May CR, Montori VM, Mair FS. Understanding patients’ experiences of treatment burden in chronic heart failure using normalization process theory. Ann Fam Med 2011;9:235–43.
pubmed: 21555751
pmcid: 3090432
doi: 10.1370/afm.1249
May C, Montori VM, Mair FS. We need minimally disruptive medicine. Br Med J 2009;339:b2803.
doi: 10.1136/bmj.b2803
Committee on Improving the Quality of Cancer Care: Addressing the challenges of an aging population, Board on Health Care Services, Institute of Medicine. In: Levit L, Balogh E, Nass S, Ganz PA (eds). Delivering high-quality cancer care: charting a new course for a system in crisis. National Academies Press (US): Washington (DC), 2013.
Ernstmann N, Herden J, Weissbach L, Karger A, Hower K, Ansmann L. Prostate-specific health-related quality of life and patient-physician communication - a 3.5-year follow-up. Patient Educ Couns 2019;102:2114–21.
pubmed: 31399225
doi: 10.1016/j.pec.2019.07.030
Ayanian JZ, Zaslavsky AM, Guadagnoli E, Fuchs CS, Yost KJ, Creech CM, et al. Patients’ perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol 2005;23:6576–86.
pubmed: 16116149
doi: 10.1200/JCO.2005.06.102
Freeman HP, Reuben SH. Voices of a broken system: real people, real problems. President’s Cancer Panel Report of the Chairman. 2000;2001.
Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, et al. Decision making about surgery for early-stage breast cancer. J Am Coll Surg 2012;214:1–10.
pubmed: 22056355
doi: 10.1016/j.jamcollsurg.2011.09.017
Zikmund-Fisher BJ, Couper MP, Singer E, Ubel PA, Ziniel S, Fowler FJ Jr., et al. Deficits and variations in patients’ experience with making 9 common medical decisions: the DECISIONS survey. Med Decis Mak 2010;30:85s–95s.
doi: 10.1177/0272989X10380466
Geng H-M, Chuang D-M, Yang F, Yang Y, Liu W-M, Liu L-H, et al. Prevalence and determinants of depression in caregivers of cancer patients: a systematic review and meta-analysis. Medicine 2018;97:e11863.
pubmed: 30278483
pmcid: 6181540
doi: 10.1097/MD.0000000000011863
Harden JK, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, et al. Partners’ long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatment. Cancer Nurs 2013;36:104–13.
pubmed: 22728952
doi: 10.1097/NCC.0b013e3182567c03
Sambasivam R, Liu J, Vaingankar JA, Ong HL, Tan ME, Fauziana R, et al. The hidden patient: chronic physical morbidity, psychological distress, and quality of life in caregivers of older adults. Psychogeriatrics 2019;19:65–72.
pubmed: 30182505
doi: 10.1111/psyg.12365
Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 2011;7:371–4.
pubmed: 22379419
pmcid: 3219463
doi: 10.1200/JOP.2011.000460
Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018;68:153–65.
pubmed: 29338071
pmcid: 6652174
doi: 10.3322/caac.21443
de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017;123:476–84.
doi: 10.1002/cncr.30369
pubmed: 27716900
Catt S, Starkings R, Shilling V, Fallowfield L. Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review. J Cancer Surviv 2017;11:211–32.
pubmed: 27834041
doi: 10.1007/s11764-016-0580-1
Stokes ME, Ishak J, Proskorovsky I, Black LK, Huang Y. Lifetime economic burden of prostate cancer. BMC Health Serv Res 2011;11:349.
pubmed: 22204308
pmcid: 3276437
doi: 10.1186/1472-6963-11-349
Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A. Direct cost for initial management of prostate cancer: a systematic review. Curr Oncol 2013;20:e522–31.
pubmed: 24311952
pmcid: 3851348
doi: 10.3747/co.20.1630
Raval AD, Madhavan S, Mattes MD, Sambamoorthi U. Association between types of chronic conditions and cancer stage at diagnosis among elderly Medicare beneficiaries with prostate cancer. Popul Health Manag 2016;19:445–53.
pubmed: 27031642
pmcid: 5296923
doi: 10.1089/pop.2015.0141
Walker V, Perret-Guillaume C, Kesse-Guyot E, Agrinier N, Hercberg S, Galan P, et al. Effect of multimorbidity on health-related quality of life in adults aged 55 years or older: results from the SU.VI.MAX 2 cohort. PLoS ONE 2016;11:e0169282.
pubmed: 28033414
pmcid: 5199105
doi: 10.1371/journal.pone.0169282
Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017;72:521–31.
pubmed: 28089304
doi: 10.1016/j.eururo.2016.12.025
Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011;12:703–08.
pubmed: 21354373
doi: 10.1016/S1470-2045(10)70294-1
Chiumento C, Fiorentino A, Cozzolino M, Caivano R, Clemente S, Pedicini P, et al. Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy. Chin J Cancer Res 2013;25:274–80.
pubmed: 23825903
pmcid: 3696714
Wei MY, Kawachi I, Okereke OI, Mukamal KJ. Diverse cumulative impact of chronic diseases on physical health-related quality of life: implications for a measure of multimorbidity. Am J Epidemiol 2016;184:357–65.
pubmed: 27530335
pmcid: 5013885
doi: 10.1093/aje/kwv456
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4:365–80.
pubmed: 26814148
pmcid: 4708226
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.
pubmed: 15082523
doi: 10.1210/er.2002-0032
Janssen Ortho LLC ZYTIGA (abiraterone acetate) US prescribing information. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ZYTIGA-pi.pdf . Accessed July 22, 2019.
Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19:43–9.
pubmed: 23337756
pmcid: 3788593
doi: 10.1097/PPO.0b013e318282635a
Astellas Pharma US Inc. Xtandi (enzalutamide) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415s014lbl.pdf . Accessed June 11, 2019.
Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf . Accessed December 13, 2019.
Food and Drug Administration. Prescribing information: ERLEADA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf . Accessed June 11, 2019.
Gul A, Garcia JA, Barata PC. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide. Cancer Manag Res 2019;11:7253–62.
pubmed: 31534371
pmcid: 6682169
doi: 10.2147/CMAR.S165706
McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol 2019;37:923–31.
pubmed: 30811282
pmcid: 7051849
doi: 10.1200/JCO.18.01777
Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis 2020;23:207–19.
pubmed: 31844181
doi: 10.1038/s41391-019-0195-5
Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825–36.
pubmed: 25097095
doi: 10.1016/j.eururo.2014.07.010
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378:2465–74.
pubmed: 29949494
pmcid: 8288034
doi: 10.1056/NEJMoa1800536
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl J Med 2020;382:2197–206.
pubmed: 32469184
doi: 10.1056/NEJMoa2003892
Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl J Med 2014;371:1755–6.
pubmed: 25354111
doi: 10.1056/NEJMoa1405095
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl J Med 2012;367:1187–97.
pubmed: 22894553
doi: 10.1056/NEJMoa1207506
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl J Med 2018;378:1408–18.
pubmed: 29420164
doi: 10.1056/NEJMoa1715546
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021; 79:150–158.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl J Med 2019;380:1235–46.
pubmed: 30763142
doi: 10.1056/NEJMoa1815671
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl J Med 2020;383:1040–49.
pubmed: 32905676
doi: 10.1056/NEJMoa2001342
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 2019;75:285–93.
pubmed: 30119985
doi: 10.1016/j.eururo.2018.07.035
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 2016;27:286–94.
pubmed: 26578735
doi: 10.1093/annonc/mdv542
Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benefits 2017;10:143–53.
pubmed: 28626511
pmcid: 5470240
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437–46.
pubmed: 20398925
pmcid: 2948179
doi: 10.1016/S0140-6736(10)60172-9
Williams S, Mazibuko N, O’Daly O, Zurth C, Patrick F, Woolridge C, et al. Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. J Clin Oncol 2020;38:abstr 326.
doi: 10.1200/JCO.2020.38.6_suppl.326
Sandmann S, Trummel D, Seidel D, Nubbemeyer R, Gieschen H, Zurth C Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. ASCO Genitourinary Cancers Symposium; 14–16 February; San Francisco.
Zurth C, Sandmann S, Trummel D, Seidel D, Gieschen H. Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography. J Clin Oncol 2018;36:345.
doi: 10.1200/JCO.2018.36.6_suppl.345
Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
pubmed: 26137992
pmcid: 4490394
doi: 10.1038/srep12007
van Haastregt JC, Zijlstra GA, van Rossum E, van Eijk JT, Kempen GI. Feelings of anxiety and symptoms of depression in community-living older persons who avoid activity for fear of falling. Am J Geriatr Psychiatry 2008;16:186–93.
pubmed: 18310549
doi: 10.1097/JGP.0b013e3181591c1e
Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009;12:198–203.
pubmed: 18852703
doi: 10.1038/pcan.2008.51
Network NCC. National Comprehensive Cancer Network clinical practice guidelines in oncology: cancer-related fatigue. https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf . Accessed July 6, 2020.
Galvao DA, Taaffe DR, Spry N, Newton RU. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 2007;10:340–6.
pubmed: 17486110
doi: 10.1038/sj.pcan.4500975
Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol 2017;72:293–99.
pubmed: 28249801
doi: 10.1016/j.eururo.2017.02.019
Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil 2015;96:7–14.
pubmed: 25194450
doi: 10.1016/j.apmr.2014.08.010
Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force symposium and update since 2012. J Pain Symptom Manag 2015;50:830–41.
doi: 10.1016/j.jpainsymman.2015.06.019
Cherrier MM, Anderson K, David D, Higano CS, Gray H, Church A, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 2013;93:617–22.
pubmed: 24012579
doi: 10.1016/j.lfs.2013.08.011
Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 2015;24:1360–7.
doi: 10.1002/pon.3769
pubmed: 25759235
Sutton E, Hackshaw-McGeagh LE, Aning J, Bahl A, Koupparis A, Persad R, et al. The provision of dietary and physical activity advice for men diagnosed with prostate cancer: a qualitative study of the experiences and views of health care professionals, patients and partners. Cancer Causes Control 2017;28:319–29.
pubmed: 28220328
pmcid: 5357268
doi: 10.1007/s10552-017-0861-7
Kaiser A, Haskins C, Siddiqui MM, Hussain A, D’Adamo C. The evolving role of diet in prostate cancer risk and progression. Curr Opin Oncol 2019;31:222–29.
pubmed: 30893147
pmcid: 7379157
doi: 10.1097/CCO.0000000000000519
Li H, Hodgson E, Watson L, Shukla A, Nelson JJ. Comorbidities and concomitant medication use in men with prostate cancer or high levels of PSA compared to matched controls: a GPRD analysis. J Cancer Epidemiol 2012;2012:291704.
pubmed: 22570655
pmcid: 3335188
doi: 10.1155/2012/291704
Fleshner K, Tin A, Benfante N, Carlsson S, Vickers AJ. Comparison of physician-documented versus patient-reported collection of comorbidities among patients with prostate cancer upon first visit to the urology clinic. JCO Clin Cancer Inform 2018;2:1–10.
pubmed: 30652570
doi: 10.1200/CCI.17.00154
Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Evaluation of clinically relevant drug–drug interactions with darolutamide in the phase 3 ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer. Target Oncol 2019;14:527–39.
pubmed: 31571095
pmcid: 6797643
doi: 10.1007/s11523-019-00674-0
Astellas. Xtandi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415s014lbl.pdf . Accessed September 26, 2018.
Janssen Ortho LLC. Erleada (apalutamide) US prescribing information. Revised 09/2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ERLEADA-pi.pdf . Accessed October 21, 2020.
Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev 2017;55:71–82.
doi: 10.1016/j.ctrv.2017.03.001
Pollock Y, Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). J Clin Oncol 2019;37:5025.
doi: 10.1200/JCO.2019.37.15_suppl.5025
Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, et al. Drug–drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet 2019;44:747–59.
pubmed: 31571146
pmcid: 6828636
doi: 10.1007/s13318-019-00577-5
Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008;113:1097–106.
pubmed: 18666210
doi: 10.1002/cncr.23658
Treanor CJ, Li J, Donnelly M. Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care 2017;26:e12642.
doi: 10.1111/ecc.12642
Coons SJ, Eremenco S, Lundy JJ, O’Donohoe P, O’Gorman H, Malizia W. Capturing patient-reported outcome (PRO) data electronically: the past, present, and promise of ePRO measurement in clinical trials. Patient 2015;8:301–09.
pubmed: 25300613
doi: 10.1007/s40271-014-0090-z
Lucas SM, Kim TK, Ghani KR, Miller DC, Linsell S, Starr J, et al. Establishment of a web-based system for collection of patient-reported outcomes after radical prostatectomy in a statewide quality improvement collaborative. Urology 2017;107:96–102.
pubmed: 28652160
doi: 10.1016/j.urology.2017.04.058
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1404–16.
pubmed: 30213449
doi: 10.1016/S1470-2045(18)30456-X
Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:556–69.
pubmed: 30770294
doi: 10.1016/S1470-2045(18)30898-2
Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre MA, Mohamed AF, et al. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). ASCO; May 31–June 4; Chicago, USA.
Protopapa E, van der Meulen J, Moore CM, Smith SC. Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments. BJU Int 2017;120:468–81.
pubmed: 28437031
doi: 10.1111/bju.13896
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2020;38:abstr 5516.
doi: 10.1200/JCO.2020.38.15_suppl.5516
Fizazi K, Shore ND, Tammela T, Ulys A, Vjaters E, Polyakov S, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2020;38:abstr 5514.
doi: 10.1200/JCO.2020.38.15_suppl.5514
Poquet N, Lin C. The Brief Pain Inventory (BPI). J Physiother 2016;62:52.
pubmed: 26303366
doi: 10.1016/j.jphys.2015.07.001
Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H, Timilshina N, et al. Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer. J Urol 2018;200:327–34.
pubmed: 29477720
doi: 10.1016/j.juro.2018.02.073
Von Ah D, Jansen CE, Allen DH. Evidence-based interventions for cancer- and treatment-related cognitive impairment. Clin J Oncol Nurs 2014;18(Suppl):17–25.
doi: 10.1188/14.CJON.S3.17-25
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 1997;13:63–74.
doi: 10.1016/S0885-3924(96)00274-6
Morris C, Gibbons E, Fitzpatrick R Patient reported outcome measures. http://phi.uhce.ox.ac.uk/pdf/CancerReviews/PROMs_Oxford_Prostate%20Cancer_012011.pdf . Accessed December 18, 2018.
Okuyama T, Akechi T, Kugaya A, Okamura H, Shima Y, Maruguchi M, et al. Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manag 2000;19:5–14.
doi: 10.1016/S0885-3924(99)00138-4
Hinz A, Mehnert A, Kocalevent RD, Brähler E, Forkmann T, Singer S, et al. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry. 2016;16:22.
Teng E, Becker BW, Woo E, Knopman DS, Cummings JL, Lu PH. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer’s disease. Alzheimer Dis Assoc Disord 2010;24:348–53.
pubmed: 20592580
pmcid: 2997338
doi: 10.1097/WAD.0b013e3181e2fc84
Marshall GA, Zoller AS, Lorius N, Amariglio R, Locascio J, Johnson K, et al. Functional activities questionnaire items that best discriminate and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res 2015;12:493–502.
pubmed: 26017560
pmcid: 4448081
doi: 10.2174/156720501205150526115003
Pickard AS, Ray S, Ganguli A, Cella D. Comparison of FACT- and EQ-5D–based utility scores in cancer. Value Health 2012;15:305–11.
pubmed: 22433762
doi: 10.1016/j.jval.2011.11.029
Devlin N, Herdman M, Pavesi M, Phung, Naidoo S, Beer TM, et al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes 2017;15:130.
pubmed: 28645287
pmcid: 5481866
doi: 10.1186/s12955-017-0704-y